In conclusion, while the data strongly support the clinical exploration of EphA3 CAR T cells in glioma treatment, it is paramount to consider the intertumor and intratumor heterogeneity that may influence therapeutic outcomes. The gene discussed is EPHA3; the disease is central nervous system cancer.